31 January 2024 - Designation is based on preliminary safety and efficacy data from an on-going Phase 1/2 trial in patients with platinum-resistant ovarian epithelial cancer, fallopian tube, or primary peritoneal cancer.
BioNTech and Duality Biologics today announced that the US FDA granted fast track designation for BNT325/DB-1305 for the treatment of patients with platinum-resistant ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer who have received one to three prior systemic treatment regimens.